Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $4.6 million.

  • Entrada Therapeutics' Gains from Investment Securities fell 3500.00% to -$36,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 90.22%. This contributed to the annual value of $4.6 million for FY2024, which is 94.04% down from last year.
  • As of FY2024, Entrada Therapeutics' Gains from Investment Securities stood at $4.6 million, which was down 94.04% from $77.6 million recorded in FY2023.
  • Entrada Therapeutics' Gains from Investment Securities' 5-year high stood at $77.6 million during FY2023, with a 5-year trough of $331,000 in FY2021.
  • In the last 3 years, Entrada Therapeutics' Gains from Investment Securities had a median value of $4.6 million in 2024 and averaged $28.8 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Gains from Investment Securities skyrocketed by 1,688.47% in 2023, and later crashed by 94.04% in 2024.
  • Over the past 5 years, Entrada Therapeutics' Gains from Investment Securities (Yearly) stood at $541,000 in 2020, then plummeted by 38.82% to $331,000 in 2021, then surged by 1,210.57% to $4.3 million in 2022, then surged by 1,688.47% to $77.6 million in 2023, then crashed by 94.04% to $4.6 million in 2024.